TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 749193
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy alone (control)
Study: 749193
Drug: Chemotherapy programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy programs (further random allocation)
Study: 30818837
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral therapy (ICBT)
Study: 22686551
Drug: Face-to-face cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive-behavioral therapy (CBT)
Study: 31774494
Drug: Training models
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training models for implementing evidence-based psychological treatment
Study: 19632949
Drug: S-1 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 combined with platinum compounds, irinotecan, and gemcitabine
Study: 11906552
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant concurrent chemoradiotherapy (PCCRT)
Study: 11906552
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (PCT)
Study: 11588535
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg, once daily)
Study: 8031705
Drug: Enalapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10-40 mg, once daily)
Study: 2590930
Drug: 7F catheter
Normalized name: pneumococcal capsular polysaccharide type 7F vaccine
DrugBank: Streptococcus pneumoniae type 7f capsular polysaccharide antigen (DB10325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7F catheter (hand injection)
Study: 2590930
Drug: 5F catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5F catheter (hand injection)
Study: 2590930
Drug: 5F catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5F catheter (power injection)
Study: 5090759
Drug: Dermatological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatological treatment plus psychiatric treatment (limited to four months)
Study: 5090759
Drug: Dermatological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatological treatment only
Study: 28974124
Drug: Low-dose Dhaka
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Dhaka regime
Study: 28974124
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose only regime
Study: 22381714
Drug: Avagacestat (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat (0.3 to 800 mg)
Study: 20299490
Drug: Triple stimulus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple stimulus (GHRP-2/GHRH/l-arginine)
Study: 16334715
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10-day decrescendo therapy of methadone only)
Study: 12921571
Drug: Combined chemoradiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemoradiotherapy (Group A) - chemotherapy with 5‐fluorouracil and cisplatin for 2 cycles and radiotherapy of DT36 Gy/12 f/17 d followed by surgery
Study: 11234740
Drug: VAQTA (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAQTA (hepatitis A vaccine)
Study: 11234740
Drug: HAVRIX (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAVRIX (hepatitis A vaccine)
Study: 24867312
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of latanoprost or physiological buffered saline solution (group 5 and 6)
Study: 19016201
Drug: Intracameral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral cefuroxime 1 mg in 0.1 mL isotonic NaCl solution
Study: 16261220
Drug: Bicyclol 150
Normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicyclol 150 mg daily
Study: 16261220
Drug: Bicyclol 75
Normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicyclol 75 mg daily
Study: 12021520
Drug: Me‐Cbl 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Me‐Cbl 500 microg twice/week plus FA 10 mg/day
Study: 12021520
Drug: FA 10
Normalized name: IDHIFA 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA 10 mg/day alone
Study: 12021520
Drug: Me‐Cbl 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Me‐Cbl 500 microg twice/week alone (Control Group D)
Study: 1835324
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (54 micrograms after the first isoetharine treatment and 36 micrograms after the second and fourth treatments)
Study: 1835324
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of nebulized isoetharine (0.5 mL of a 1% solution diluted to 2.0 mL with normal saline every hour)
Study: 31113987
Drug: esaxerenone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: esaxerenone 1.25 mg/day
Study: 31113987
Drug: esaxerenone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: esaxerenone 2.5 mg/day
Study: 31113987
Drug: esaxerenone 5
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: esaxerenone 5 mg/day
Study: 31113987
Drug: eplerenone (50–100
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone (50–100 mg/day)
Study: 26514931
Drug: Amoxicillin 100mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 100mg/kg/day + 0.9% NSI
Study: 26514931
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + 0.9% NSI
Study: 25073939
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity ambulatory rehabilitation programmes (≥ 3 × 1‐h weekly sessions for approximately 10 weeks)
Study: 25073939
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care programmes (≤ 2 × 1‐h weekly sessions)
Study: 21084399
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (25-75 mg daily)
Study: 17556785
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (CT)
Study: 15191514
Drug: Lansoprazole, clarithromycin
Normalized name: lansoprazole, clarithromycin and tinidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, clarithromycin and tinidazole twice‐daily
Study: 15191514
Drug: Lansoprazole, clarithromycin
Normalized name: lansoprazole, clarithromycin and tinidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, clarithromycin and tinidazole once‐daily
Study: 15191514
Drug: Placebo, clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, clarithromycin and tinidazole once‐daily
Study: 15191514
Drug: Lansoprazole, clarithromycin
Normalized name: lansoprazole, clarithromycin and tinidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, clarithromycin and tinidazole (both dosing regimens)
Study: 11753827
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of secondary prophylaxis against cytomegalovirus (CMV)
Study: 9834046
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg 4 times a day) for 10 days with concomitant clarithromycin (500 mg twice a day) from days 6 through 10
Study: 9834046
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice a day) for 10 days combined with cisapride (10 mg 4 times a day) from days 6 through 10
Study: 9834046
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg 4 times a day)
Study: 24434382
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice a day)
Study: 9706623
Drug: Vigabatrin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 150 mg/kg/day
Study: 9706623
Drug: Vigabatrin 65-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 65-75 mg/kg/day
Study: 6703348
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 5 mg
Study: 6703348
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 7.5 mg
Study: 6859570
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 7.5 mg
Study: 26206451
Drug: Vaginal hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal hysterectomy with suspension of the uterosacral ligaments
Study: 22537824
Drug: Smoking and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking and SE alleles combination
Study: 20167988
Drug: Pre-emptive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive therapy with valganciclovir (n=36)
Study: 15858814
Drug: Optimized pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized pharmacological treatment (n=8)
Study: 9147710
Drug: Egifilin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egifilin 200 mg retard tablet
Study: 9147710
Drug: Egifilin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egifilin 400 mg retard tablet
Study: 3555852
Drug: Physostigmine and
Normalized name: Physostigmine and pilocarpine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine and lecithin combination
Study: 20972285
Drug: RUTF (locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTF (locally produced energy-dense supplement)
Study: 18333868
Drug: Maraviroc 900
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 900 mg
Study: 18333868
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (active comparator)
Study: 18333868
Drug: Maraviroc (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (all doses)
Study: 18333868
Drug: Maraviroc (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (up to 2363 ng ml(‐1))
Study: 8554016
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy (intravenous thrombolytic agents or urgent percutaneous transluminal coronary angioplasty)
Study: 1320913
Drug: Metoclopramide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (3 mg/kg) plus dexamethasone (12 mg)
Study: 1320913
Drug: Chlorpromazine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (up to 200 mg/24 h) plus dexamethasone (12 mg)
Study: 30391914
Drug: Continuous infusions
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusions of vancomycin (CIV)
Study: 25156622
Drug: Alemtuzumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (30 mg intraoperatively)
Study: 25156622
Drug: Rabbit anti-thymocyte
Normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit anti-thymocyte globulin (multiple doses starting intraoperatively)
Study: 12097201
Drug: Radioiodine and
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine and lithium group (Li group) - lithium carbonate, 300 mg three times a day for 3 weeks starting on the day of radioiodine administration
Study: 9858319
Drug: AVONEX (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVONEX (6 MIU single i.m. dose)
Study: 22503722
Drug: Ca-group: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca-group: 500 mg/d calcium
Study: 22503722
Drug: Ca+MZ-group: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca+MZ-group: 500 mg/d calcium + multivitamin tablet containing 15 mg/d zinc
Study: 22503722
Drug: C-group: multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-group: multivitamin tablet without any minerals
Study: 8618250
Drug: Multiple-dose activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose activated charcoal (six doses) and two doses of sorbitol over 24 hours
Study: 6626409
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with diazepam 5 mg rectally and atropine 0.3‐0.4 mg sublingually (Group A)
Study: 6289856
Drug: Rectal combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal combination of diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Study: 26879200
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 50 mg weekly for up to 8 years
Study: 26879200
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 50 mg weekly for up to 8 years with vitamin D3 (5600 IU) and calcium supplementation
Study: 17846812
Drug: Methylphenidate Spheroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate Spheroidal Oral Drug Absorption System (MPH-SODAS)
Study: 10390392
Drug: Aerosolized uridine-5'-triphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized uridine-5'-triphosphate (UTP) 5 mg/ml, 3.5 ml
Study: 10390392
Drug: Vehicle (0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (0.12% saline, 3.5 ml)
Study: 9071082
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (2.5 mg in 3 ml)
Study: 9071082
Drug: Nebulized metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized metaproterenol (15 mg in 3 ml)
Study: 9071082
Drug: Nebulized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized saline 3 ml (control group)
Study: 1864451
Drug: 0.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/day Imedeen for 90 days
Study: 6401426
Drug: Intranasal nitroglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nitroglycerine (NTG) administered 1 min before induction of anaesthesia
Study: 30286760
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) 70 ml (6.5 mmol NO3‐)
Study: 26712474
Drug: Unscheduled health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unscheduled health care visits for asthma or use of oral corticosteroids in the previous year
Study: 26712474
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and post-bronchodilator ratios of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC)
Study: 21966995
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg (with optional dose escalation to 8 mg at week 4)
Study: 20300709
Drug: Prevention programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention programs and interventions in the field of drug abuse
Study: 17950801
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dabigatran plus aspirin
Study: 17950801
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dabigatran
Study: 17950801
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dabigatran
Study: 17950801
Drug: Dabigatran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (50 mg, 150 mg, 300 mg)
Study: 12089124
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) plus spacer (400 microg, 4 puffs)
Study: 12089124
Drug: Small Volume
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small Volume Nebuliser (SVN) (0.15 mg/kg)
Study: 7497601
Drug: Carboplatin 42
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 42 mg/m2 per day
Study: 7497601
Drug: Carboplatin 35
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 35 mg/m2 per day
Study: 2841905
Drug: Carboplatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (all doses)
Study: 1645990
Drug: Anesthetic solutions
Normalized name: Gelato Anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic solutions with added sodium bicarbonate
Study: 1645990
Drug: Anesthetic solutions
Normalized name: Gelato Anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic solutions without added sodium bicarbonate
Study: 7021261
Drug: Flufenamic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flufenamic acid, 100 mg, four times daily
Study: 7021261
Drug: Paracetamol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (up to 8 x 500 mg daily)
Study: 30266874
Drug: Premature birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature birth and not being cared by the biological parent
Study: 27552352
Drug: High-Power Pain
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Power Pain Threshold (HPPT) ultrasound therapy
Study: 17305652
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 mg for 2 months and then 8 mg daily
Study: 12029412
Drug: Slow endotracheal
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow endotracheal surfactant infusion
Study: 12029412
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of surfactant
Study: 9836210
Drug: Alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 15 micrograms.kg‐1 followed by propofol 4 mg.kg‐1 with lignocaine 0.2 mg.kg‐1
Study: 9836210
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microgram.kg‐1 followed by propofol 4 mg.kg‐1 with lignocaine 0.2 mg.kg‐1
Study: 962994
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy and specific active immunotherapy (C+I)
Study: 962994
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (C)
Study: 25448491
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy plus lenalidomide (DLBCL-len)
Study: 25448491
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (DLBCL-c)
Study: 23883653
Drug: Renal denervation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal denervation on top of medical treatment
Study: 8235664
Drug: 10MTX (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10MTX (10 mg/M2/wk)
Study: 8235664
Drug: D-penicillamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (10 mg/kg/d)
Study: 8235664
Drug: Hydroxychloroquine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (6 mg/kg/d)
Study: 8235664
Drug: Auranofin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (0.15 to 0.20 mg/kg/d)
Study: 8235664
Drug: 5MTX (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5MTX (5 mg/M2/wk)
Study: 27803033
Drug: Bevacizumab, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, cisplatin, and paclitaxel (bevacizumab 15 mg/kg, cisplatin 50 mg/m2, paclitaxel 135 mg/m2 over 24 h or 175 mg/m2 over 3 h) administered every 3 weeks until disease progression or unacceptable toxicity.
Study: 25475358
Drug: Phenylephrine 10
Normalized name: phenylephrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 10 mg with acetaminophen 1000 mg
Study: 25475358
Drug: Phenylephrine 10
Normalized name: phenylephrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 10 mg with acetaminophen 500 mg
Study: 25475358
Drug: Phenylephrine 5
Normalized name: phenylephrine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 5 mg with acetaminophen 1000 mg
Study: 24067392
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C tablet (50 mg)
Study: 15575172
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol (50 microg/gm cream applied twice daily)
Study: 15575172
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol (ointment)
Study: 11052493
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug, acetaminophen, or placebo for 2 weeks
Study: 8554733
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg daily)
Study: 3910706
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (600 mg/day, 2 days before and 6 days after surgery)
Study: 23020133
Drug: TRAP (thrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAP (thrombin receptor activating peptide)
Study: 20124218
Drug: Oral 6-thioguanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 6-thioguanine (TG)
Study: 20124218
Drug: Oral 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 6-mercaptopurine (MP)
Study: 12161768
Drug: Phentolamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (40 mg)
Study: 12828169
Drug: Urapidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (25 mg intravenously)
Study: 12828169
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg intravenously)
Study: 8792442
Drug: 20mg low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg low dose aspirin
Study: 8792442
Drug: 40mg low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg low dose aspirin
Study: 8792442
Drug: 80mg low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80mg low dose aspirin